Company has extensive liquid manufacturing capacity across multiple global regions. However, the company’s facility footprint and capabilities were designed to support the high volume needs of large scale mAb customers. As such, the company doesn’t have the capability to efficiently make small to medium scale custom cGMP liquids.
The lack of scalable cGMP process liquid manufacturing assets has negatively impacted the company’s ability to adequately serve the rapidly growing Cell and Gene Therapy Market which generally require lot sizes much smaller than traditional biotech customers.
The company required new capabilities to offer a compelling and differentiated solution to end-customers in the C> market space.
GeminiBio offered the company a compelling value proposition based on GeminiBio’s diversity of cGMP process liquid manufacturing capabilities, including 500-liter, 1,000-liter, 5,000-liter, and 10,000-liter single use and stainless-steel mixing vessels.
GeminiBio collaborated with the company to complete an extensive audit process and define the end-to-end business processes to efficiently execute end-customer custom product proposals developed by the company’s commercial field sales teams. As part of the contract manufacturing agreement, GeminiBio committed to market-leading service level agreements (SLAs) to ensure the customer was able to provide an industry leading customer experience to their C> end customers.
By leveraging GeminiBio’s scalable liquid manufacturing capabilities (10-liters to 10,000-liters), rapid feasibility, and custom product design process, as well as 10-week manufacturing lead times, the company was able to dramatically improve their competitive position within the C> market.